Shire Pharmaceuticals Group plc
TSX : SHQ
NASDAQ : SHPGY
LSE : SHP

Shire Pharmaceuticals Group plc

September 13, 2005 13:55 ET

Special Meeting of the Holders of Exchangeable Shares of Shire Acquisition Inc.

MONTREAL, QUEBEC--(CCNMatthews - Sept. 13, 2005) - Shire Acquisition Inc. ("Shire Acquisition") (TSX:SHQ)(NASDAQ:SHPGY)(LSE:SHP) announced that it will be mailing a management information circular to the holders of exchangeable shares later this month in connection with a special meeting of the holders of exchangeable shares which will be held on Friday October 21st, 2005 at 10:00 a.m. (EST) to consider, and if thought fit, approve a special resolution, with or without amendment, authorizing:



(i) amendments to the articles of Shire Acquisition,

(ii) the termination of the exchangeable share support agreement
made as of May 11, 2001 among Shire Acquisition, Shire
Pharmaceuticals Group plc ("SPG") and 3829359 Canada Inc.
("CallCo"),

(iii) the termination of the voting and exchange trust agreement
made as of May 11, 2001 among Shire Acquisition, SPG and Natcan
Trust Company (as successor to National Bank Trust and the
General Trust of Canada) (the "Trustee"),

(iv) the entering into of an exchangeable share support agreement
among Shire Acquisition, Shire plc (i.e., SPG's new holding
company) ("Shire") and CallCo, and

(v) the entering into of a voting and exchange trust agreement
among Shire Acquisition, Shire and the Trustee,


all of such changes to, or in, the rights of the holders of, the exchangeable shares being required to maintain the equivalence of such exchangeable shares and the ordinary shares of SPG following the implementation of the proposed scheme of arrangement between SPG and its holders of ordinary shares under section 425 of the UK Companies Act 1985, as announced by SPG in its press release dated September 8, 2005 entitled "Shire to introduce a new UK listed holding company to create distributable reserves".

Notes to editors

Shire Acquisition Inc.

Shire Acquisition is an indirect wholly owned subsidiary of SPG. The exchangeable shares of Shire Acquisition are listed on the Toronto Stock Exchange and are convertible into three ordinary shares of SPG or one ADS representing three ordinary shares of SPG. SPG's ordinary shares are listed on the London Stock Exchange and SPG's ADSs are listed on NASDAQ.

Shire Pharmaceuticals Group plc

SPG is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), renal diseases and genetic diseases. SPG has operations in the world's key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.

For further information, please visit the company's website: www.shire.com.

Contact Information

  • Investor Relations:
    Shire Acquisition Inc.
    Brian Piper (North America)
    1 (484) 595-8252
    or
    Shire Acquisition Inc.
    Clea Rosenfeld (Rest of the World)
    44 1256 894 160
    or
    Media:
    Shire Acquisition Inc.
    Matthew Cabrey (North America)
    1 (484) 595-8248
    or
    Shire Acquisition Inc.
    Jessica Mann (Rest of the World)
    44 1256 894 280